Internal Medicine, Endocrinology, Diabetes, & Metabolism · Miami, FL
NPI
1477627842
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1200 SW 1st St
Miami, FL, 33135
Phone (305) 961-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,529
23 services
Medicare patients, 2024
21
Average age 71
Drug cost, 2024
$4.5M
10,969 prescriptions
Company payments, 2025
$530
From 14 companies
Medicare prescription drug claims, 2024
In 2024, the drug Oberto Torres Rafael prescribed most often to Medicare patients was Metformin Hcl, with 919 prescriptions and refills. In total Oberto Torres Rafael wrote 10,969 Medicare prescriptions that cost $4.5M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-09.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Metformin Hcl Generic | 919 | 2,299 | 269 | $3,673 |
| Novolog Flexpen Insulin Aspart | 820 | 1,284 | 171 | $125K |
| Trulicity Dulaglutide | 665 | 700 | 89 | $664K |
| Ozempic Semaglutide | 659 | 713 | 86 | $667K |
| Levothyroxine Sodium Generic | 621 | 1,451 | 172 | $7,494 |
| Mounjaro Tirzepatide | 474 | 496 | 59 | $513K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 431 | 859 | 110 | $37K |
| Xultophy 100-3.6 Insulin Degludec/Liraglutide | 381 | 469 | 63 | $471K |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | 286 | 390 | 52 | $229K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 272 | 541 | 66 | $119K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 261 | 369 | 44 | $245K |
| Rosuvastatin Calcium Generic | 253 | 611 | 79 | $1,694 |
| Glyxambi Empagliflozin/Linagliptin | 248 | 313 | 41 | $184K |
| Pioglitazone Hcl Generic | 242 | 539 | 68 | $2,321 |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 228 | 326 | 39 | $154K |
Brand drugs: 6,458 claims; generic drugs: 3,217 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Oberto Torres Rafael $530 ($530 in general payments such as food, travel and fees) from 14 companies. The largest payer was Tandem Diabetes Care, Inc. with $96.06.
| Company | Payments | Amount |
|---|---|---|
| Tandem Diabetes Care, Inc. TNDM | 4 | $96.06 |
| Xeris Pharmaceuticals, Inc. | 4 | $76.5 |
| Lilly USA, LLC LLY | 3 | $50.62 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $46.99 |
| Medtronic, Inc. MDT | 1 | $46.36 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $30.53 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $27.83 |
| Amgen Inc. AMGN | 1 | $26.71 |
| Insulet Corporation PODD | 1 | $24.01 |
| Mannkind Corporation MNKD | 1 | $24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.